|
| 36726221 | A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. | | 2023 |
| 35658469 | Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. | Journal of Clinical Oncology | 2023 |
| 36357295 | Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. | Clinical Lymphoma, Myeloma and Leukemia | 2023 |
| 35468618 | Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. | Blood advances | 2023 |
| 37708911 | Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. | | 2023 |
| 37783970 | Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. | Nat Med | 2023 |
| 37621165 | Measurable residual disease in peripheral blood in myeloma: dream or reality. | | 2023 |
| 37691005 | Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis | | 2023 |
| 37270762 | Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. | | 2023 |
| 36763537 | Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. | | 2023 |
| 36642080 | Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. | | 2023 |
| 36494017 | Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. | | 2023 |
| 36546453 | Adjusted comparison of outcomes between patients from CARTITUDE-1 multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world cl | | 2023 |
| 34871550 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. | Lancet Oncology, The | 2022 |
| 35974364 | Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. | Journal of Hematology and Oncology | 2022 |
| 35462406 | Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. | Oncologist | 2022 |
| 36358748 | Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. | Cancers | 2022 |
| 35821020 | Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. | Blood Cancer Journal | 2022 |
| 36215989 | Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. | Lancet Haematology,The | 2022 |
| 35732350 | Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. | Journal for ImmunoTherapy of Cancer | 2022 |
| 35549810 | Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. | Leukemia and Lymphoma | 2022 |
| 35418120 | Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. | Blood Cancer Journal | 2022 |
| 35862034 | Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. | JAMA Oncology | 2022 |
| 35922273 | Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2022 |
| 36379208 | Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. | Cancer Cell | 2022 |
| 36799429 | A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. | | 2022 |
| 34269818 | Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. | Blood | 2022 |
| 34315721 | Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025. | Clinical Cancer Research | 2022 |
| 35210399 | Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. | Blood Cancer Journal | 2022 |
| 34479756 | Knowing the unknowns in high risk multiple myeloma. | Blood Reviews | 2022 |
| 34470049 | Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. | Blood advances | 2021 |
| 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet, The | 2021 |
| 34078314 | Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. | BMC Cancer | 2021 |
| 33535838 | Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. | Leukemia and Lymphoma | 2021 |
| 34274290 | Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. | Clinical Lymphoma, Myeloma and Leukemia | 2021 |
| 33563912 | Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. | Blood Cancer Journal | 2021 |
| 34039952 | Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). | Blood Cancer Journal | 2021 |
| 33216365 | Sex differences in outcomes in multiple myeloma. | British Journal of Haematology | 2021 |
| 33162369 | Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. | Journal of Geriatric Oncology | 2021 |
| 32778736 | International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. | Leukemia | 2021 |
| 32605900 | Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |
| 32325490 | Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. | Blood | 2020 |
| 31969330 | First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. | Clinical Cancer Research | 2020 |
| 32078124 | Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. | Advances in Therapy | 2020 |
| 32124443 | Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. | British Journal of Haematology | 2020 |
| 31836199 | Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. | Lancet, The | 2020 |
| 32054831 | Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. | Blood Cancer J | 2020 |
| 31940591 | Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. | Journal for ImmunoTherapy of Cancer | 2020 |
| 31714026 | Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. | Cancer Medicine | 2020 |
| 32278674 | Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. | Clinical Lymphoma, Myeloma and Leukemia | 2020 |